Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-AnalysisReport as inadecuate

Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis - Download this document for free, or read online. Document in PDF available to download.

Gastroenterology Research and Practice - Volume 2016 2016, Article ID 1459790, 11 pages -

Research Article

Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China

The First Clinical Medical College, Nanjing Medical University, Nanjing 210029, China

The First Affiliated Hospital of Soochow University, Suzhou 215006, China

Received 21 January 2016; Accepted 18 July 2016

Academic Editor: Michel Kahaleh

Copyright © 2016 Wenxia Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


A meta-analysis was conducted to assess the effect of omega-3 fatty acid supplementation n-3 PUFAs in lowering liver fat, liver enzyme alanine aminotransferase ALT, aspartate aminotransferase AST, and gamma-glutamyltransferase GGT levels, and blood lipids triglyceride TG, total cholesterol TC, high density lipoprotein HDL, and low density lipoprotein LDL in patients with nonalcoholic fatty liver disease NAFLD or nonalcoholic steatohepatitis NASH. Methods. MEDLINE-PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, Science Citation Index ISI Web of Science, Chinese Biomedical Literature Database CBM, and Chinese National Knowledge Infrastructure CNKI were searched for relevant randomized controlled trials on the effects of n-3 polyunsaturated fatty acids PUFAs in patients with NAFLD from inception to May 2015. Ten studies were included in this meta-analysis. Results. 577 cases of NAFLD-NASH in ten randomized controlled trials RCTs were included. The results of the meta-analysis showed that benefit changes in liver fat favored PUFA treatment, and it was also beneficial for GGT, but it was not significant on ALT, AST, TC, and LDL. Conclusions. In this meta-analysis, omega-3 PUFAs improved liver fat, GGT, TG, and HDL in patients with NAFLD-NASH. Therefore, n-3 PUFAs may be a new treatment option for NAFLD.

Author: Wenxia Lu, Sainan Li, Jingjing Li, Jianrong Wang, Rong Zhang, Yuqing Zhou, Qin Yin, Yuanyuan Zheng, Fan Wang, Yujing Xia,

Source: https://www.hindawi.com/


Related documents